U.S. Markets open in 7 hrs 29 mins

Bristol-Myers Squibb Company (BMY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
54.21+0.11 (+0.20%)
At close: 4:02PM EDT
People also watch
MRKLLYABTPFEJNJ

Bristol-Myers Squibb Company

345 Park Avenue
New York, NY 10154
United States
212-546-4000
http://www.bms.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees25,000

Key Executives

NameTitlePayExercisedAge
Dr. Giovanni Caforio M.D.Chairman and Chief Exec. Officer5.11M3.17M52
Mr. Charles A. BancroftChief Financial Officer, Head of Global Bus. Operations and Exec. VP2.85MN/A57
Dr. Thomas J. Lynch Jr., M.D.Chief Scientific Officer and Exec. VP152.5kN/A56
Ms. Sandra LeungExec. VP and Gen. Counsel2.45M5.17M56
Mr. Murdo GordonChief Commercial Officer and Exec. VP1.85MN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company’s products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreement with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Corporate Governance

Bristol-Myers Squibb Company’s ISS Governance QualityScore as of May 1, 2017 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 4; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.